Developing Anticancer Drugs in Orphan Molecular Entities - A Paradigm under Construction.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. The complexity of finding fit-for-purpose real-world data for oncology patients with rareESMO real world data and digital oncology · 2025
   Article
2. Embracing cancer complexity: Hallmarks of systemic disease.Cell · 2024
   Review
3. New clinical trial design in precision medicine: discovery, development and direction.Signal transduction and targeted therapy · 2024
   Review
4. Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer.ESMO open · 2024
   Review
5. How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers.Journal of cancer education : the official journal of the American Association for Cancer Education · 2020
   Article
6. A paradigm shift in biomarker guided oncology drug development.Annals of translational medicine · 2019
   Review
7. Impact of a novel prioritization framework on clinician-led oncology drug submissions.Current oncology (Toronto, Ont.) · 2019
   Article
8. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.Journal of medicinal chemistry · 2019
   Article
9. Basket Trials for Intractable Cancer.Frontiers in oncology · 2019
   Review
10. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2018
    Review

Corrections and comments

• Comment on
  Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as